Skip to main
FTH

FTH Stock Forecast & Price Target

FTH Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Faeth Therapeutics is a company with a promising pipeline of drugs, including PIKTOR, which has shown positive results in clinical trials and has potential for approval. The recent acquisition and partnership with SenseiBiotherapeutics provides further resources and expertise for future development and expansion. While competition and challenges may exist in the market, the development of interval dosing and potential for combination therapy provide opportunities for growth and success in treating endometrial and breast cancer.

Bears say

Faeth Therapeutics is a clinical-stage biotechnology company with a potential treatment, PIKTOR, for ER+/HER2- breast cancer and endometrial cancer. While its drug has shown promise in clinical trials, there are several other competitors with similar agents, raising concerns about market saturation. Additionally, the company was recently acquired, which may indicate a lack of confidence in its ability to reach success on its own. There is also a lack of data on long-term efficacy and potential side effects, making it difficult to fully evaluate the potential of the drug and the company's overall outlook.

FTH has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sensei Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sensei Biotherapeutics Inc (FTH) Forecast

Analysts have given FTH a Buy based on their latest research and market trends.

According to 4 analysts, FTH has a Buy consensus rating as of Jul 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sensei Biotherapeutics Inc (FTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.